Edwards Lifesciences (EW) Amortization of Deferred Charges (2021 - 2026)

Edwards Lifesciences' Amortization of Deferred Charges history runs 6 years deep, the most recent figure standing at $6.5 million for Q1 2026.

• On a quarterly basis, Amortization of Deferred Charges rose 6.56% year-over-year to $6.5 million in Q1 2026; TTM through Mar 2026 was $26.3 million, a 0.38% change from a year earlier, with the FY2025 full-year figure at $25.9 million, down 6.83% from the prior year.
• Amortization of Deferred Charges retreated to $6.5 million in Q1 2026 per EW's latest filing, from $6.6 million in the prior quarter.
• Across five years, Amortization of Deferred Charges topped out at $7.7 million in Q1 2024 and bottomed at $6.1 million in Q1 2025.
• The 5-year median for Amortization of Deferred Charges is $6.8 million (2022), against an average of $6.8 million.
• Across the five-year window, Amortization of Deferred Charges grew 13.64% in 2023 and dropped 20.78% in 2025, its largest moves.
• Year by year, Amortization of Deferred Charges stood at $6.6 million in 2022, then climbed by 13.64% to $7.5 million in 2023, then slipped by 17.33% to $6.2 million in 2024, then climbed by 6.45% to $6.6 million in 2025, then declined by 1.52% to $6.5 million in 2026.
• Per Business Quant, the three latest EW Amortization of Deferred Charges figures stand at $6.5 million (Q1 2026), $6.6 million (Q4 2025), and $6.8 million (Q3 2025).